Skip to main content Accessibility help
×
Home

Impact of Antibiotic Use during Hospitalization on the Development of Gastrointestinal Colonization with Escherichia coli with Reduced Fluoroquinolone Susceptibility

  • Jennifer H. Han (a1) (a2) (a3), Warren B. Bilker (a2) (a3), Irving Nachamkin (a4), Pam Tolomeo (a2), Xiangqun Mao (a4), Neil O. Fishman (a1) and Ebbing Lautenbach (a1) (a2) (a3)...

Abstract

Objective.

Infections due to fluoroquinolone-resistant Escherichia coli (FQREC) are associated with significant morbidity and mortality. Fluoroquinolone resistance likely arises at the level of gastrointestinal colonization. The objective of this study was to identify risk factors for the development of FQREC gastrointestinal tract colonization in hospitalized patients, including the impact of antibiotics prescribed during hospitalization.

Design.

A prospective cohort study was conducted from 2002 to 2004 within a university health system.

Methods.

Hospitalized patients initially colonized with fluoroquinolone-susceptible E. coli were followed up with serial fecal sampling for new FQREC colonization or until hospital discharge or death. A Cox proportional hazards regression model was developed to identify risk factors for new FQREC colonization, with antibiotic exposure modeled as time-varying covariates.

Results.

Of 395 subjects, 73 (18.5%) became newly colonized with FQREC. Length of stay before sampling (hazard ratio [HR], 1.02 [95% confidence interval (CI), 1.1–1.03]; P = .003) and malignancy (HR, 0.37 [95% CI, 0.21–0.67]; P = .001) were significantly associated with the development of FQREC colonization. In addition, receipt of a first-generation cephalosporin (HR, 1.19 [95% CI, 1.10–1.29]; P<.001) or cefepime (HR, 1.05 [95% CI, 1.00–1.10]; P = .048) during hospitalization increased the risk of new FQREC colonization.

Conclusions.

The acquisition of FQREC in the hospital setting is complex, and antimicrobial stewardship programs should take into account patterns of antibiotic use in implementing strategies to reduce the development of new FQREC colonization. Future studies are needed to identify risk factors for infection in hospitalized patients newly colonized with FQREC.

Copyright

Corresponding author

Division of Infectious Diseases, Department of Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, 3rd Floor, Silverstein Building, Suite E, Philadelphia, PA 19104 (jennifer.han@uphs.upenn.edu)

References

Hide All
1.Linder, JA, Huang, ES, Steinman, MA, Gonzales, R, Stafford, RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005;118:259268.
2.Lautenbach, E, Strom, BL, Nachamkin, I, et al.Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989–2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004;38:655662.
3.Camins, BC, Marschall, J, DeVader, SR, Maker, DE, Hoffman, MW, Fraser, VJ. The clinical impact of fluoroquinolone resistance in patients with E. coli bacteremia. J Hosp Med 2011;6:344349.
4.Lautenbach, E, Metlay, JP, Bilker, WB, Edelstein, PH, Fishman, NO. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections the role of inadequate empirical antimicrobial therapy. Clin Infect Dis 2005;41:923929.
5.Chang, TM, Lu, PL, Li, HH, Chang, CY, Chen, TC, Chang, LL. Characterization of fluoroquinolone resistance mechanisms and their correlation with the degree of resistance to clinically used fluoroquinolones among Escherichia coli isolates. J Chemother 2007;19:488494.
6.Singh, R, Swick, MC, Ledesma, KR, et al.Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother 2012;56:16801685.
7.Kern, WV, Oethinger, M, Jellen-Ritter, AS, Levy, SB. Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 2000;44: 814820.
8.Donskey, CJ. Antibiotic regimens and intestinal colonization with antibiotic-resistant gram-negative bacilli. Clin Infect Dis 2006;43(suppl 2):S62S69.
9.Richard, P, Delangle, MH, Raffi, F, Espaze, E, Richet, H. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora. Clin Infect Dis 2001;32:162166.
10.Lautenbach, E, Fishman, NO, Bilker, WB, et al.Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002;162:24692477.
11.Johnson, L, Sabel, A, Burman, WJ, et al.Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med 2008;121:876884.
12.van der Starre, WE, van Nieuwkoop, C, Paltansing, S, et al.Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother 2011;66:650656.
13.Huotari, K, Tarkka, E, Valtonen, V, Kolho, E. Incidence and risk factors for nosocomial infections caused by fluoroquinolone-resistant Escherichia coli. Eur J Clin Microbiol Infect Dis 2003;22:492495.
14.Lin, CY, Huang, SH, Chen, TC, Lu, PL, Lin, WR, Chen, YH. Risk factors of ciprofloxacin resistance in urinary Escherichia coli isolates. J Microbiol Immunol Infect 2008;41:325331.
15.Arslan, H, Azap, OK, Ergonul, O, Timurkaynak, F. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005;56:914918.
16.Ortega, M, Marco, F, Soriano, A, et al.Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 2009;63:568574.
17.Colodner, R, Kometiani, I, Chazan, B, Raz, R. Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli. Infection 2008;36:4145.
18.McDonald, LC, Chen, FJ, Lo, HJ, et al.Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob Agents Chemother 2001;45:30843091.
19.Killgore, KM, March, KL, Guglielmo, BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother 2004;38:11481152.
20.Lautenbach, E, Metlay, JP, Weiner, MG, et al.Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance. Infect Control Hosp Epidemiol 2009;30:1824.
21.de Lastours, V, Chau, F, Tubach, F, Pasquet, B, Ruppe, E, Fantin, B. Independent behavior of commensal flora for carriage of fluoroquinolone-resistant bacteria in patients at admission. Antimicrob Agents Chemother 2010;54:51935200.
22.Hota, BN, Pur, S, Phillips, L, Weinstein, RA, Segreti, J. Impact of a fluoroquinolone formulary change on acquisition of quinolone-resistant gram-negative bacilli. Eur J Clin Microbiol Infect Dis 2005;24:405410.
23.Yagci, D, Yoruk, F, Azap, A, Memikoglu, O. Prevalence and risk factors for selection of quinolone-resistant Escherichia coli strains in fecal flora of patients receiving quinolone therapy. Antimicrob Agents Chemother 2009;53:12871289.
24.Perea, S, Hidalgo, M, Arcediano, A, et al.Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis. J Antimicrob Chemother 1999;44:117120.
25.Lautenbach, E, Fishman, NO, Metlay, JP, et al.Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative. J Infect Dis 2006;194:7985.
26.Gales, AC, Gordon, KA, Wilke, WW, Pfaller, MA, Jones, RN. Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America. Diagn Microbiol Infect Dis 2000;36:6164.
27.Lee, I, Fishman, NO, Zaoutis, TE, et al.Risk factors for fluconazole-resistant Candida glabrata bloodstream infections. Arch Intern Med 2009;169:379383.
28.Barton, TD, Fishman, NO, Weiner, MG, LaRosa, LA, Lautenbach, E. High rate of coadministration of di- or tri-valent cation-containing compounds with oral fluoroquinolones: risk factors and potential implications. Infect Control Hosp Epidemiol 2005;26:9399.
29.Mickey, RM, Greenland, S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989;129:125137.
30.Han, JH, Nachamkin, I, Tolomeo, P, Mao, X, Bilker, WB, Lautenbach, E. Temporal changes in resistance mechanisms in colonizing Escherichia coli isolates with reduced susceptibility to fluoroquinolones. Diagn Microbiol Infect Dis 2013;76:491496.
31.Hyle, EP, Bilker, WB, Gasink, LB, Lautenbach, E. Impact of different methods for describing the extent of prior antibiotic exposure on the association between antibiotic use and antibiotic-resistant infection. Infect Control Hosp Epidemiol 2007;28:647654.
32.Keeney, D, Ruzin, A, McAleese, F, Murphy, E, Bradford, PA. MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli. J Antimicrob Chemother 2008;61:4653.
33.Swick, MC, Morgan-Linnell, SK, Carlson, KM, Zechiedrich, L. Expression of multidrug efflux pump genes acrAB-tolC, mdfA, and norE in Escherichia coli clinical isolates as a function of fluoroquinolone and multidrug resistance. Antimicrob Agents Chemother 2011;55:921924.
34.Sahm, DF, Critchley, IA, Kelly, LJ, et al.Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance. Antimicrob Agents Chemother 2001;45:267274.
35.Han, JH, Nachamkin, I, Tolomeo, P, Mao, X, Bilker, WB, Lautenbach, E. Risk factors for efflux pump overexpression in fluoroquinolone-resistant Escherichia coli. J Infect Dis 2012;206:15971603.
36.Bolon, MK, Wright, SB, Gold, HS, Carmeli, Y. The magnitude of the association between fluoroquinolone use and quinolone-resistant Escherichia coli and Klebsiella pneumoniae may be lower than previously reported. Antimicrob Agents Chemother 2004;48:19341940.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed